$17.00
At close: Apr 15 EDT
$16.95
-0.05-0.29%
Pre-Market: 7:16 AM EDT
Comments
Loading...
Beam Therapeutics Analyst Ratings and Price Targets | NASDAQ:BEAM | Benzinga
Beam Therapeutics Inc has a consensus price target of $55.05 based on the ratings of 21 analysts. The high is $113 issued by SVB Leerink on August 10, 2022. The low is $26 issued by RBC Capital on February 26, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., B of A Securities, and Scotiabank on April 7, 2025, March 28, 2025, and March 10, 2025, respectively. With an average price target of $54 between HC Wainwright & Co., B of A Securities, and Scotiabank, there's an implied 218.58% upside for Beam Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
B of A Securities
Scotiabank
Jones Trading
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Beam Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/07/2025 | Buy Now | 371.98% | HC Wainwright & Co. | Patrick Trucchio41% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2025 | Buy Now | 147.79% | B of A Securities | Alec Stranahan33% | $42 → $42 | Upgrade | Neutral → Buy | Get Alert |
| 03/12/2025 | Buy Now | — | Cantor Fitzgerald | Rick Bienkowski26% | — | Reiterates | Overweight → Overweight | Get Alert |
| 03/10/2025 | Buy Now | 135.99% | Scotiabank | Greg Harrison40% | → $40 | Upgrade | Sector Perform → Sector Outperform | Get Alert |
| 03/10/2025 | Buy Now | 100.59% | Jones Trading | Soumit Roy31% | → $34 | Upgrade | Hold → Buy | Get Alert |
| 03/10/2025 | Buy Now | 371.98% | HC Wainwright & Co. | Patrick Trucchio41% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2025 | Buy Now | 47.49% | Scotiabank | Greg Harrison40% | $24 → $25 | Maintains | Sector Perform | Get Alert |
| 02/28/2025 | Buy Now | 371.98% | HC Wainwright & Co. | Patrick Trucchio41% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 360.18% | Guggenheim | Debjit Chattopadhyay48% | $78 → $78 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 53.39% | RBC Capital | Luca Issi36% | $24 → $26 | Maintains | Sector Perform | Get Alert |
| 02/03/2025 | Buy Now | 371.98% | HC Wainwright & Co. | Patrick Trucchio41% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2025 | Buy Now | — | Cantor Fitzgerald | Rick Bienkowski26% | — | Upgrade | Neutral → Overweight | Get Alert |
| 12/09/2024 | Buy Now | 371.98% | HC Wainwright & Co. | Patrick Trucchio41% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | 371.98% | HC Wainwright & Co. | Patrick Trucchio41% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2024 | Buy Now | 41.59% | RBC Capital | Luca Issi36% | $27 → $24 | Maintains | Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | 130.09% | Leerink Partners | Rick Bienkowski26% | $27 → $39 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/16/2024 | Buy Now | 41.59% | Scotiabank | Greg Harrison40% | → $24 | Initiates | → Sector Perform | Get Alert |
| 09/19/2024 | Buy Now | 59.29% | RBC Capital | Luca Issi36% | $27 → $27 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | — | Jones Trading | Soumit Roy31% | — | Initiates | → Hold | Get Alert |
| 09/11/2024 | Buy Now | 307.08% | Stifel | Benjamin Burnett42% | $66 → $69 | Maintains | Buy | Get Alert |
| 08/22/2024 | Buy Now | 371.98% | HC Wainwright & Co. | Patrick Trucchio41% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 183.19% | JP Morgan | Eric Joseph43% | $45 → $48 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 82.89% | Barclays | Gena Wang50% | $33 → $31 | Maintains | Equal-Weight | Get Alert |
| 08/07/2024 | Buy Now | 59.29% | RBC Capital | Luca Issi36% | $27 → $27 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 07/23/2024 | Buy Now | 371.98% | HC Wainwright & Co. | Patrick Trucchio41% | → $80 | Initiates | → Buy | Get Alert |
| 05/08/2024 | Buy Now | 94.69% | Barclays | Gena Wang50% | $42 → $33 | Maintains | Equal-Weight | Get Alert |
| 04/23/2024 | Buy Now | 236.28% | Wedbush | David Nierengarten59% | $57 → $57 | Reiterates | Outperform → Outperform | Get Alert |
| 03/27/2024 | Buy Now | 236.28% | BMO Capital | Kostas Biliouris32% | → $57 | Maintains | Outperform | Get Alert |
| 02/28/2024 | Buy Now | 147.79% | Barclays | Gena Wang50% | $26 → $42 | Maintains | Equal-Weight | Get Alert |
| 02/28/2024 | Buy Now | 106.49% | RBC Capital | Luca Issi36% | $27 → $35 | Maintains | Sector Perform | Get Alert |
| 01/29/2024 | Buy Now | 135.99% | JP Morgan | Eric Joseph43% | $38 → $40 | Upgrade | Neutral → Overweight | Get Alert |
| 12/15/2023 | Buy Now | 106.49% | B of A Securities | Greg Harrison40% | → $35 | Downgrade | Buy → Neutral | Get Alert |
| 12/08/2023 | Buy Now | 76.99% | Jefferies | Michael Yee55% | $75 → $30 | Downgrade | Buy → Hold | Get Alert |
| 10/17/2023 | Buy Now | 88.79% | Cantor Fitzgerald | Rick Bienkowski26% | $56 → $32 | Maintains | Overweight | Get Alert |
| 09/13/2023 | Buy Now | 230.38% | Cantor Fitzgerald | Rick Bienkowski26% | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | Buy Now | 230.38% | Cantor Fitzgerald | Rick Bienkowski26% | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 106.49% | Barclays | Gena Wang50% | $41 → $35 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | Buy Now | 177.29% | Credit Suisse | Richard Law41% | $46 → $47 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | 230.38% | Citigroup | Samantha Semenkow33% | $60 → $56 | Maintains | Buy | Get Alert |
| 05/11/2023 | Buy Now | 147.79% | RBC Capital | Luca Issi36% | $50 → $42 | Maintains | Sector Perform | Get Alert |
| 05/11/2023 | Buy Now | 141.89% | Barclays | Gena Wang50% | $45 → $41 | Maintains | Equal-Weight | Get Alert |
| 05/11/2023 | Buy Now | 253.98% | Citigroup | Samantha Semenkow33% | $62 → $60 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | 118.29% | Bernstein | William Pickering36% | → $37 | Initiates | → Market Perform | Get Alert |
| 03/01/2023 | Buy Now | 519.47% | Wells Fargo | Yanan Zhu36% | $125 → $105 | Maintains | Overweight | Get Alert |
| 02/01/2023 | Buy Now | 265.78% | Cantor Fitzgerald | Rick Bienkowski26% | → $62 | Initiates | → Overweight | Get Alert |
| 01/23/2023 | Buy Now | 354.28% | SVB Leerink | Mani Foroohar48% | $81 → $77 | Maintains | Outperform | Get Alert |
| 12/20/2022 | Buy Now | 289.38% | BMO Capital | Kostas Biliouris32% | $61 → $66 | Upgrade | Market Perform → Outperform | Get Alert |
| 12/13/2022 | Buy Now | 265.78% | Citigroup | Samantha Semenkow33% | → $62 | Initiates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | 212.68% | Credit Suisse | Richard Law41% | $65 → $53 | Maintains | Neutral | Get Alert |
| 11/07/2022 | Buy Now | 377.88% | SVB Leerink | Mani Foroohar48% | $82 → $81 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 253.98% | Barclays | Gena Wang50% | $38 → $60 | Maintains | Equal-Weight | Get Alert |
| 08/10/2022 | Buy Now | 566.67% | SVB Leerink | Rick Bienkowski26% | $118 → $113 | Maintains | Outperform | Get Alert |
| 06/17/2022 | Buy Now | 141.89% | BMO Capital | Kostas Biliouris32% | → $41 | Initiates | → Market Perform | Get Alert |
| 05/09/2022 | Buy Now | 613.86% | SVB Leerink | Rick Bienkowski26% | $118 → $121 | Maintains | Outperform | Get Alert |
| 04/28/2022 | Buy Now | 265.78% | Credit Suisse | Richard Law41% | → $62 | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ:BEAM) was reported by HC Wainwright & Co. on April 7, 2025. The analyst firm set a price target for $80.00 expecting BEAM to rise to within 12 months (a possible 371.98% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Beam Therapeutics (BEAM)?
The latest analyst rating for Beam Therapeutics (NASDAQ:BEAM) was provided by HC Wainwright & Co., and Beam Therapeutics reiterated their buy rating.
When was the last upgrade for Beam Therapeutics (BEAM)?
The last upgrade for Beam Therapeutics Inc happened on March 28, 2025 when B of A Securities raised their price target to $42. B of A Securities previously had a neutral for Beam Therapeutics Inc.
When was the last downgrade for Beam Therapeutics (BEAM)?
The last downgrade for Beam Therapeutics Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $35 for Beam Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on April 7, 2025 so you should expect the next rating to be made available sometime around April 7, 2026.
Is the Analyst Rating Beam Therapeutics (BEAM) correct?
While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a reiterated with a price target of $80.00 to $80.00. The current price Beam Therapeutics (BEAM) is trading at is $16.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.